SCHEMBL3664095

SCHEMBL3664095

CC(C)(C)OC(=O)CCNCCNC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
GAA P10253 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
EPHX1 P07099 1/20 0.45
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA12 O43570 3/20 0.42
CA9 Q16790 3/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HIF1A Q16665 1/20 0.41
MALT1 Q9UDY8 1/20 0.40
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2153714 0.91 TDP1 (0.49) TDP1MAOAMAOBGAAMEN1
SCHEMBL2799440 0.89 TDP1 (0.56) TDP1MAOAMAOBGAAMEN1
SCHEMBL631719 0.89 TDP1 (0.60) TDP1MAOAMAOBGAAMEN1
SCHEMBL20801639 0.89 TDP1 (0.60) TDP1MAOAMAOBGAAMEN1
SCHEMBL9998912 0.89 TDP1 (0.60) TDP1MAOAMAOBGAAMEN1
SCHEMBL19560876 0.87 TDP1 (0.45) TDP1MAOAMAOBGAAMEN1
SCHEMBL3485766 0.87 EPHX2 (0.40) TDP1MAOAMAOBGAAMEN1
SCHEMBL10149390 0.86 MEN1 (0.51) TDP1MAOAMAOBGAAMEN1
SCHEMBL25963753 0.86 TDP1 (0.50) TDP1MAOAMAOBGAAMEN1
SCHEMBL1025400 0.84 MAOA (0.58) TDP1MAOAMAOBGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217621-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-04-22 EP disclosed
US-8710000-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-04-29 US disclosed
US-20100279931-A1 Insulin Derivative NOVO NORDISK A/S 2010-11-04 US disclosed
EP-2217621-A1 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2010-08-18 EP disclosed
WO-2009060071-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2009-05-14 WO disclosed
EP-2058330-A1 Insulin derivative NOVO NORDISK A/S (DK) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279931-A1 Insulin Derivative IAPP, INSR, GPR119 TDP1 4552/4885MAOA 4462/4885MAOB 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.